What NYHA functional class and ACC/AHA stage correspond to congestive heart failure with an ejection fraction of 20–25%?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Classification of CHF with EF 20-25%

An ejection fraction of 20-25% definitively classifies the patient as having Heart Failure with Reduced Ejection Fraction (HFrEF), which corresponds to ACC/AHA Stage C heart failure. The NYHA functional class cannot be determined by ejection fraction alone—it depends entirely on the patient's current symptoms and functional limitations 1.

Understanding the Classification Systems

ACC/AHA Stage Classification

With an EF of 20-25%, this patient has Stage C heart failure by definition, as they have structural heart disease with reduced ejection fraction 1. Stage C specifically indicates "structural heart disease with prior or current symptoms of HF" 1.

  • Stage A: At risk but no structural disease or symptoms
  • Stage B: Structural disease but no symptoms
  • Stage C: Structural disease with prior or current symptoms (this patient)
  • Stage D: Refractory HF requiring specialized interventions

NYHA Functional Class - Symptom-Based Assessment

The NYHA class is completely independent of ejection fraction and must be determined by assessing the patient's functional capacity 1:

  • Class I: No limitation of physical activity; ordinary activity does not cause HF symptoms
  • Class II: Slight limitation; comfortable at rest, but ordinary activity causes symptoms
  • Class III: Marked limitation; comfortable at rest, but less than ordinary activity causes symptoms
  • Class IV: Unable to perform any activity without symptoms, or symptoms at rest

Critical Clinical Considerations

Why EF Doesn't Determine NYHA Class

Research demonstrates substantial overlap in objective measures across NYHA classes 2. Patients with severely reduced EF (20-25%) can range from asymptomatic (Class I) to severely symptomatic (Class IV). The evidence shows:

  • Mortality varies significantly even within the same NYHA class across different populations 2
  • There is 60-88% overlap in objective measures (NT-proBNP, 6-minute walk distance) between NYHA Class I and II patients 3, 2
  • Peak oxygen consumption is a more reliable predictor of prognosis than NYHA class alone 4

Practical Assessment Algorithm

To determine NYHA class for this patient with EF 20-25%:

  1. Ask about dyspnea with ordinary activities (walking, climbing stairs, household tasks)

    • No symptoms → Class I
    • Symptoms with ordinary activity → Class II
    • Symptoms with minimal activity → Class III
    • Symptoms at rest → Class IV
  2. Assess functional capacity objectively if classification is uncertain:

    • 6-minute walk test distance
    • NT-proBNP levels (though overlap exists between classes)
    • Patient self-assessment using Visual Analogue Scale 3

Treatment Implications

This severely reduced EF (20-25%) mandates aggressive guideline-directed medical therapy (GDMT) regardless of NYHA class 5, 6:

  • ACE inhibitors or ARNIs
  • Beta-blockers (carvedilol, metoprolol succinate, or bisoprolol)
  • Mineralocorticoid receptor antagonists (aldosterone antagonists) - specifically indicated for LVEF ≤35% 5, 6
  • SGLT2 inhibitors
  • Diuretics for volume management

Device therapy consideration: With EF 20-25%, the patient likely qualifies for ICD evaluation if they are NYHA Class II-III on optimal medical therapy 7.

Common Pitfall

Do not assume severe LV dysfunction (EF 20-25%) automatically means severe symptoms. Some patients with this degree of systolic dysfunction remain minimally symptomatic (NYHA Class I-II), while others are severely limited (Class III-IV). The classification systems serve different purposes: ACC/AHA stages track disease progression and structural changes, while NYHA class guides symptom management and device eligibility 1.

References

Research

Clinical Implications of the New York Heart Association Classification.

Journal of the American Heart Association, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.